Vercise Deep Brain Stimulation (DBS) Systems
Boston Scientific Corp · Decision date Oct 30, 2026
What did the FDA decide?
The FDA recorded a decision dated 2026-10-30 on supplement P150031/S102 for the Vercise Deep Brain Stimulation (DBS) Systems, submitted by Boston Scientific Corp. The supplement was filed as a 30-Day Notice under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the recorded decision is OK30. The device category is an implanted electrical stimulator for parkinsonian symptoms, with product code NHL and Neurology as the specialty.
The recorded scope is narrow: approval to increase the mold temperature parameter used in the injection molding process for manufacturing the seal stack component. This is a manufacturing process parameter change for one component, not a new approval of the Vercise DBS system as a whole, and the source does not describe clinical data, sterilization effects or the seal stack's role in the finished device. The source also does not state what OK30 denotes or the basis for the decision, so those points remain unknown.
FDA approval order statement
approval to increase the mold temperature parameter used in the injection molding process for manufacturing the seal stack component
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150031/S102
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- Decision code
- OK30
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian symptoms.
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150031 · Original PMA
VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM
P150031/S084 · Related supplement
VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEM
P150031/S098 · Related supplement
Vercise Genus DBS Systems; Vercise Gevia DBS Systems
P150031/S102 received
Application receipt date recorded by FDA.
P150031/S100 · Related supplement
Vercise DBS Systems
P150031/S102 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P150031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA approval | Dec 8, 2017 | FDA | |
VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEMP150031/S084 | Boston Scientific Corp | PMA supplement | Sep 13, 2026 | FDA |
| Boston Scientific Corp | PMA supplement | Sep 22, 2026 | FDA | |
Vercise DBS SystemsP150031/S100 | Boston Scientific Corp | PMA supplement | Oct 15, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 25155 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P150031/S102
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

